Therapy with the triplet routine of zanzalintinib (XL092) plus Opdivo (nivolumab) and Opdualag (relatlimab-rmbw) is a therapy choice price exploring in sufferers with beforehand untreated clear cell renal cell carcinoma, a kind of kidney most cancers, defined Dr. Michael Serzan in an interview with CURE.
The part 1b research shared information from the dose-expansion cohort of the trial on the 2025 ASCO Annual Assembly, which reported that when evaluating the triplet mixture with a doublet of simply zanzalintinib and Opdivo, the triplet truly had a decrease general response charge (63% versus 40%). Regardless of this, Serzan says that the mixture remains to be price exploring.
It’s also necessary to notice that whereas the median follow-up for the doublet arm was 20.1 months, the median comply with up for the triplet arm was simply 15.9 months, that means there’s nonetheless a methods to go along with exploring this therapy mixture.
Serzan is a medical oncologist within the Lank Middle for Genitourinary Oncology at Dana-Farber Most cancers Institute, in addition to an teacher of medication at Harvard Medical Faculty, positioned in Boston.
Transcript:
This was a comparatively small research — a part 1 trial with solely 80 sufferers, 40 in every arm — designed primarily to see how nicely this mix was tolerated. Once we attempt to evaluate it with at the moment out there choices, it’s necessary to recollect these are totally different research with totally different affected person populations and drugs, so it’s not an ideal comparability. Nonetheless, we are likely to make these comparisons anyway.
What I might say in regards to the outcomes from STELLAR-002 is that the unintended effects within the doublet — zanzalintinib plus Opdivo — versus the triplet — zanzalintinib plus Opdivo and Opdualag — have been pretty related. A few third of sufferers skilled unintended effects, which have been [consistent] with what we usually see with a lot of these therapies. The most typical ones have been hypertension, diarrhea, liver and thyroid abnormalities, and pores and skin rash. If sufferers skilled these unintended effects, we managed them by decreasing doses or quickly holding the drugs.
One notable a part of the presentation was that only a few sufferers in both arm ended up stopping therapy altogether. Investigators appeared in a position to determine what was making the unintended effects, maintain the medicine, after which resume therapy.
As for tumor responses: within the doublet arm, we noticed a response charge of simply over 60% and a illness management charge of about 90%. Meaning about 60% of sufferers had their tumors shrink, and about 90% had their tumors shrink or keep steady.
Once we have a look at the triplet arm, we noticed considerably decrease charges — a response charge round 40%, although the illness management charge was nonetheless about 90%. Once more, small numbers right here with 40 sufferers in every arm, but it surely’s intriguing; you’d suppose that the triplet would present a better response charge versus the doublet, however we didn’t see that but on this research.
We additionally checked out progression-free survival, which was truly a bit longer within the doublet arm at about 18 months versus about 13 months for the triplet. It’s intriguing to see.
The first finish level was security and tolerability, and these combos appeared pretty related in that regard. That mentioned, it was a little bit [disappointing] that the triplet didn’t appear to provide higher or longer responses. Nonetheless, it is a mixture price exploring, particularly as we proceed looking for new medicine and regimens for sufferers with kidney most cancers.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
